BACKGROUND AND AIMS: Discrepant remission rates (41-100%) have been reported for patients with localised low grade gastric mucosa associated lymphoid tissue (MALT) lymphoma after eradication of Helicobacter pylori. The aim of this study was to explain these discrepancies and to determine the predictive factors of gastric lymphoma regression after anti- H pylori treatment. PATIENTS AND METHODS: Forty six consecutive patients with localised gastric MALT lymphoma (Ann Arbor stages I(E) and II(E)) were prospectively enrolled. All had gastric endoscopic ultrasonography and H pylori status assessment (histology, culture, polymerase chain reaction, and serology). After anti-H pylori treatment, patients were re-examined every four months. RESULTS: Histological regression of the lymphoma was complete in 19/44 patients (43%) (two lost to follow up). Median follow up time for these 19 responders was 35 months (range 10-47). No regression was noted in the 10 H pylori negative patients. Among the 34 H pylori positive patients, the H pylori eradication rate was 100%; complete regression rate of the lymphoma increased from 56% (19/34) to 79% (19/24) when there was no nodal involvement at endoscopic ultrasonography. There was a significant difference between the response of the lymphoma restricted to the mucosa and other more deep seated lesions (p<0.006). However, using multivariate analysis, the only predictive factor of regression was the absence of nodal involvement (p<0.0001). CONCLUSION: In H pylori positive patients with localised gastric MALT lymphoma, carefully evaluated and treated without any lymph node involvement assessed by endoscopic ultrasonography, complete remission of lymphoma was reached in 79% of cases.
BACKGROUND AND AIMS: Discrepant remission rates (41-100%) have been reported for patients with localised low grade gastric mucosa associated lymphoid tissue (MALT) lymphoma after eradication of Helicobacter pylori. The aim of this study was to explain these discrepancies and to determine the predictive factors of gastric lymphoma regression after anti- H pylori treatment. PATIENTS AND METHODS: Forty six consecutive patients with localised gastric MALT lymphoma (Ann Arbor stages I(E) and II(E)) were prospectively enrolled. All had gastric endoscopic ultrasonography and H pylori status assessment (histology, culture, polymerase chain reaction, and serology). After anti-H pylori treatment, patients were re-examined every four months. RESULTS: Histological regression of the lymphoma was complete in 19/44 patients (43%) (two lost to follow up). Median follow up time for these 19 responders was 35 months (range 10-47). No regression was noted in the 10 H pylori negative patients. Among the 34 H pylori positive patients, the H pylori eradication rate was 100%; complete regression rate of the lymphoma increased from 56% (19/34) to 79% (19/24) when there was no nodal involvement at endoscopic ultrasonography. There was a significant difference between the response of the lymphoma restricted to the mucosa and other more deep seated lesions (p<0.006). However, using multivariate analysis, the only predictive factor of regression was the absence of nodal involvement (p<0.0001). CONCLUSION: In H pylori positive patients with localised gastric MALT lymphoma, carefully evaluated and treated without any lymph node involvement assessed by endoscopic ultrasonography, complete remission of lymphoma was reached in 79% of cases.
Authors: M Sackmann; A Morgner; B Rudolph; A Neubauer; C Thiede; H Schulz; W Kraemer; G Boersch; P Rohde; E Seifert; M Stolte; E Bayerdoerffer Journal: Gastroenterology Date: 1997-10 Impact factor: 22.682
Authors: A Neubauer; C Thiede; A Morgner; B Alpen; M Ritter; B Neubauer; T Wündisch; G Ehninger; M Stolte; E Bayerdörffer Journal: J Natl Cancer Inst Date: 1997-09-17 Impact factor: 13.506
Authors: B Rudolph; E Bayerdörffer; M Ritter; S Müller; C Thiede; B Neubauer; N Lehn; E Seifert; P Otto; R Hatz; M Stolte; A Neubauer Journal: J Clin Oncol Date: 1997-03 Impact factor: 44.544
Authors: G Pinotti; E Zucca; E Roggero; A Pascarella; F Bertoni; A Savio; E Savio; C Capella; E Pedrinis; P Saletti; E Morandi; G Santandrea; F Cavalli Journal: Leuk Lymphoma Date: 1997-08
Authors: C Nobre-Leitão; P Lage; M Cravo; J Cabeçadas; P Chaves; A Alberto-Santos; J Correia; J Soares; F Costa-Mira Journal: Am J Gastroenterol Date: 1998-05 Impact factor: 10.864
Authors: T Lind; F Mégraud; P Unge; E Bayerdörffer; C O'morain; R Spiller; S Veldhuyzen Van Zanten; K D Bardhan; M Hellblom; M Wrangstadh; L Zeijlon; C Cederberg Journal: Gastroenterology Date: 1999-02 Impact factor: 22.682
Authors: Antoine de Mascarel; Agnès Ruskone-Fourmestraux; Anne Lavergne-Slove; Francis Megraud; Pierre Dubus; Jean-Philippe Merlio Journal: Virchows Arch Date: 2005-03-02 Impact factor: 4.064
Authors: H Ye; L Gong; H Liu; A Ruskone-Fourmestraux; D de Jong; S Pileri; C Thiede; A Lavergne; H Boot; G Caletti; T Wündisch; T Molina; B G Taal; S Elena; A Neubauer; K A Maclennan; R Siebert; E D Remstein; A Dogan; M-Q Du Journal: Gut Date: 2006-01 Impact factor: 23.059